ENCITE - A Peek Into the Future of Novel MR Imaging Reporter Probes

European Network for Cell Imaging and Tracking Expertise (ENCITE)The consortium of the project "European Network for Cell Imaging and Tracking Expertise" (ENCITE) has the ambitious mission to develop and test new MR and optical imaging methods and biomarkers to draw a more comprehensive picture of cell fate and the reaction of the immune system. In the end cell therapy shall be improved for the benefit of the European patient.

To exploit the superb spatial and temporal resolution of MRI in Molecular Imaging applications, it is necessary to improve the sensitivity and specificity of the currently available probes:

  • Sensitivity. A new high relaxivity tetrameric Gd-based agent has been shown to provide an impressive seven-fold sensitivity enhancement in respect to the commercial agents maintaining an analogous safety profile.
  • Specificity. An enzyme responsive Gd probe has been synthesized and tested. It reports about the citivity of beta-galactosidase, an enzyme largely used by biologists as reporter of gene expression.

Important advances have been made in the field of the new family of MRI-CEST agents (CEST=Chemical Exchange Saturation Transfer). These MRI probes have great advantages in respect to the classical relaxation agents. Being frequency-encoding systems, it is possible to visualize (using different colours) more probes in the same image as every CEST agent is responsive only to a specific irradiation frequency. In the project, a paramagnetic complex, present as a pair of nmr-detectable isomers, has been selected for its high sensitivity and its ability to act as pH sensor. Mapping pH appears to be an important task to get new functional information from MR images in the presence of relevant pathologies. Moreover, upon changing the Lanthanide ion in the complex, systems able to visualize different cell types have been prepared and successfully tested.

For further information, please visit:
http://www.encite.org

About the European Network for Cell Imaging and Tracking Expertise (ENCITE)
ENCITE is a four year project co-funded by the European Commission under the 7th Framework Programme and co-ordinated by the European Institute for Biomedical Imaging Research (EIBIR). It started in June 2008 and consists of 29 international scientific partners from ten countries with outstanding expertise in cell imaging and tracking.

About The European Institute for Biomedical Imaging Research (EIBIR)
The European Institute for Biomedical Imaging Research (EIBIR) is a non-profit limited liability company dedicated to the co-ordination of research. The network has the aim of co-ordinating and supporting the development of biomedical imaging technologies and the dissemination of knowledge with the ultimate goal of improving diagnosis, treatment and prevention of disease. The platform supports networking activities in research and is key to spreading good practice, promoting common initiatives and interoperability in the field of biomedical imaging research. This will generate critical mass and help coordinate research into new instrumentation, new methods, concepts and technologies.

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...

In 10 Seconds, an AI Model Detects Cance…

Researchers have developed an AI powered model that - in 10 seconds - can determine during surgery if any part of a cancerous brain tumor that could be removed remains...